ESC Premium Access

Are your atrial fibrillation (AF) patients protected from ischaemic stroke? Clinical characteristics of AF patients eligible for stroke prevention but remaining untreated in UK clinical practice

Presentation

About the speaker

Doctor Essra Ridha

Bristol-Myers Squibb Pharmaceuticals Limited , London (United Kingdom of Great Britain & Northern Ireland)
0 follower

22 more presentations in this session

Is Aspirin monotherapy effective for stroke prevention in the real world? A UK cohort study evaluating the incidence of stroke in the absence of anticoagulation in atrial fibrillation (AF)

Speaker: Doctor E. Ridha (London, GB)

Thumbnail

Poor anticoagulation control in warfarin treated atrial fibrillation patients with reduced renal function

Speaker: Doctor A. Nissen Bonde (Gentofte, DK)

Thumbnail

In-hospital mortality, length of stay and costs of treating atrial fibrillation or flutter patients admitted for intracranial hemorrhage

Speaker: Doctor E. Nguyen (Storrs, US)

Thumbnail

One-year permeability rate of left atrial appendage closure devices: high incidence of peridevice leak and lack of endothelialization

Speaker: Doctor G. Laugaudin (Montpellier, FR)

Thumbnail

Net clinical benefit of rivaroxaban compared with warfarin in patients with atrial fibrillation

Speaker: Associate Professor J. Piccini (Durham, US)

Thumbnail

Access the full session

Poster session 3 - Anticoagulation in atrial fibrillation II

Speakers: Doctor E. Ridha, Doctor E. Ridha, Doctor A. Nissen Bonde, Doctor E. Nguyen, Doctor G. Laugaudin...
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

This platform is supported by

logo Novo Nordisk